×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: AZP2006 (Serazaxine) — PSP Platform Trial Therapy
therapeutic
1,208 words
KG: ent-dise-bfd8f32d
2026-03-29
section:therapeutics
kind:therapeutic
topic:psp
topic:cbs
topic:tauopathy
Contents
AZP2006 (Serazaxine) — PSP Platform Trial Therapy
💊
Therapeutic Info
Name
AZP2006 (Serazaxine) — PSP Platform Trial Therapy
Summary
AZP2006 (serazaxine) is an oral pleiotropic drug modulating progranulin levels, selected for the PSP Platform Trial for its neuroprotective effects via lysosomal function.
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Multi-Modal CRISPR Platform for Simultaneous Editing and Mon
Score: 0.42
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
PARP1 Inhibition Therapy
Score: 0.58
TREM2-Mediated Cholesterol Dysregulation in Microglial Senes
Score: 0.57
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli
Score: 0.57
Circadian Clock-Autophagy Synchronization
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Temporal Decoupling via Circadian Clock Reset
Score: 0.52
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Ganglioside Rebalancing Therapy
Score: 0.50
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Microglial Purinergic Reprogramming
Score: 0.48
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48
Complement C1q Mimetic Decoy Therapy
Score: 0.48
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Arginine Methylation Enhancement Therapy
Score: 0.46
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.45
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.45
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.44
Complement C1q Subtype Switching
Score: 0.44
R-Loop Resolution Enhancement Therapy
Score: 0.43
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.43
Glial Glycocalyx Remodeling Therapy
Score: 0.41
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
Show 25 more
Related Analyses (17)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 12 more
Related Experiments (9)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Show 4 more